Newsround

Number 56

1 September 2013 0

Selected reports edited by Janet Fricker Study evaluates specificity and sensitivity of lung cancer screening =>New England Journal of Medicine The latest data to be published from the US National Lung Screening Trial (NLST) documents [more]

Newsround

Selected reports edited by Janet Fricker ABVD less effective and more toxic in older patients =>Journal of Clinical Oncology In patients aged 60 years or older with Hodgkin lymphoma (HL), four cycles of ABVD is [more]

Newsround

Selected reports edited by Janet Fricker Aprepitant for managing pruritus =>  Lancet Oncology Use of anaprepitant decreased the severity of pruritus induced by biological cancer treatments, an Italian pilot study reports. Pruritus (itch) is [more]

Newsround

Number 51

1 November 2012 0

Selected reports edited by Janet Fricker Glioblastoma: temozolomide offers alternative to radio-therapy in elderly patients => The Lancet Both temozolomide and hypofractionated radiotherapy should be considered as standard treatment options for elderly patients with glioblastoma, [more]

Newsround

Number 50

1 September 2012 0

Selected reports edited by Janet Fricker Preoperative chemoradio-therapy improves survival in oesophageal cancer => New England Journal of Medicine Preoperative chemoradiotherapy improves survival among patients with potentially curable oesophageal or oesophagogastric-junction cancers, a phase III [more]

Newsround

Selected reports edited by Janet Fricker Stereotactic body radiation therapy for spinal metastases => Lancet Oncology Stereotactic body radiation therapy (SBRT) delivers significant reductions in patient-reported pain and other symptoms six months post treatment, a [more]

Newsround

Complications from robotic prostatectomy no better than conventional surgery ‹ Journal of Clinical Oncology Problems with continence and sexual function are common following both robot-assisted laparoscopic radical prostatectomy (RALRP) and open retropubic radical prostatec-tomy (ORRP), [more]

Newsround

Everolimus plus octreotide improves progression-free survival in advanced NET => The Lancet The addition of everolimus to octreotide improved progression-free survival in patients with advanced neuroendocrine tumours (NETs) associated with carcinoid syndrome, the phase III [more]

Newsround

Study helps define melanoma tumour margins => The Lancet For cutaneous melanomas thicker than 2 mm resection margins of 2 cm are sufficient and safe, a collaborative study between the Swedish Melanoma Study group and [more]

1 2 3 4 11
UA-77507851-1